肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

转移性膀胱癌的**靶向治疗药物：Balversa（erdafitinib）在美国加速获批

2019-04-13 不详 网络

Balversa转移性膀胱癌Erdafitinib
关注

强生公司近日表示，FDA已经加速批准其Balversa（erdafitinib）的营销申请，以治疗携带某些FGFR基因突变的局部晚期或转移性膀胱癌患者。

强生公司近日表示，FDA已经加速批准其Balversa（erdafitinib）的营销申请，以治疗携带某些FGFR基因突变的局部晚期或转移性膀胱癌患者。FDA药物评估和研究中心血液学和肿瘤学产品办公室主任理查德·帕兹德说：“我们正处于一个更加个性化的精准医学时代。Balversa代表了第一个针对FGFR遗传变异的转移性膀胱癌患者的治疗方案”。

II期BLC2001研究显示，在87例患有局部晚期或转移性膀胱癌的患者中，每日一次口服泛FGFR酪氨酸激酶抑制剂Balversa的客观反应率为32.2％，中位反应持续时间为5.4个月。大约四分之一的参与者之前接受过抗PD-L1 / PD-1治疗。


原始出处：

http://www.firstwordpharma.com/node/1634969#axzz5kmtmGZrh

本文系梅斯医学（MedSci）原创编译整理，转载需授权!


版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2020-03-19 周虎

    #治疗药物#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2020-01-28 yb6560

    #Erdafitinib#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-11-07 anminleiryan

    #ERS#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-05-27 baoya

    #靶向治疗药物#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-04-15 12498761m56暂无昵称

    #Balversa#

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-04-15 12498768m13(暂无昵称)

    #FIT#

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-04-15 1249842em09(暂无昵称)

    #转移性#

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1921740, encodeId=5fa01921e40fe, content=<a href='/topic/show?id=4f0a6469837' target=_blank style='color:#2F92EE;'>#治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64698, encryptionId=4f0a6469837, topicName=治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=c9d3459, createdName=周虎, createdTime=Thu Mar 19 11:25:00 CST 2020, time=2020-03-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1928082, encodeId=21d719280824e, content=<a href='/topic/show?id=aa73693568' target=_blank style='color:#2F92EE;'>#Erdafitinib#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6935, encryptionId=aa73693568, topicName=Erdafitinib)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4b65161, createdName=yb6560, createdTime=Tue Jan 28 15:25:00 CST 2020, time=2020-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1878306, encodeId=d56a18e83067c, content=<a href='/topic/show?id=c157696175' target=_blank style='color:#2F92EE;'>#ERS#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6961, encryptionId=c157696175, topicName=ERS)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e93e105, createdName=anminleiryan, createdTime=Thu Nov 07 10:25:00 CST 2019, time=2019-11-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2060424, encodeId=a85e206042463, content=<a href='/topic/show?id=ba54999214e' target=_blank style='color:#2F92EE;'>#靶向治疗药物#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99921, encryptionId=ba54999214e, topicName=靶向治疗药物)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=743d308, createdName=baoya, createdTime=Mon May 27 02:25:00 CST 2019, time=2019-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331922, encodeId=635c1331922fd, content=<a href='/topic/show?id=68bc318438' target=_blank style='color:#2F92EE;'>#Balversa#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=3184, encryptionId=68bc318438, topicName=Balversa)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b78f2500065, createdName=12498761m56暂无昵称, createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1331948, encodeId=96f0133194821, content=<a href='/topic/show?id=eac1e47058' target=_blank style='color:#2F92EE;'>#FIT#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7470, encryptionId=eac1e47058, topicName=FIT)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=ac782500066, createdName=12498768m13(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1386489, encodeId=0a9f138648993, content=<a href='/topic/show?id=f08293399f9' target=_blank style='color:#2F92EE;'>#转移性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=93399, encryptionId=f08293399f9, topicName=转移性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1ac22500003, createdName=1249842em09(暂无昵称), createdTime=Mon Apr 15 06:25:00 CST 2019, time=2019-04-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1039920, encodeId=56ff10399204a, content=膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=留走人康, createdTime=Sat Apr 13 18:25:00 CST 2019, time=2019-04-13, status=1, ipAttribution=)]
    2019-04-13 留走人康

    膀胱癌真怪，明明是免疫敏感性肿瘤，为什么PD-1治疗效果不好呢？难道靶点不对？将来CD47会不会有效

    0